LETTER

Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection

Signal Transduction and Targeted Therapy (2022) 7:55

Dear Editor,

The ongoing SARS-CoV-2 pandemic has lasted for 2 years, causing a severe global impact on social development. With widespread vaccinations, the number of new infections has dropped significantly, but with the emergence of diverse novel variants of concern (VOCs) and variants of interest (VOIs), there has been a second or third epidemic wave in many countries. Multiple variants have the potential to increase transmissibility, virulence, or evade immune responses. Among them, the Beta (B.1.351) and Omicron (B.1.1.529) VOCs have significantly decreased neutralization even in fully vaccinated individuals, while the Delta VOC (B.1.617.2) has been reported to be more infectious and has indeed become globally dominant.1,2 All currently licensed vaccines are designed based on the first-reported strain and exhibit deficient cross-neutralization against variants, highlighting the risk for health care and other service workers. In addition, due to the imbalance of global development, many countries still cannot obtain ample vaccines. Furthermore, studies have shown that cats and dogs are also susceptible to SARS-CoV-2, and there is currently no vaccine for pets.3 Given that current vaccine supplies are inadequate to meet the global demand and that it is challenging to reformulate existing vaccines to include diverse SARS-CoV-2 spike (S) antigens in a short time, so a safe, deployable, and broadly protective intervention against new emerging viruses has become particularly urgent.

Compared with vaccination, passive antibody administration can provide immediate immunity to protect susceptible persons. Convalescent plasma and monoclonal antibodies (mAbs) have been used to treat COVID-19, and multiple mAbs have been authorized for emergency use. However, antibody therapies are administered chiefly in hospitalized patients with severe pneumonia due to their high price. Furthermore, Omicron VOC caused more than 85% of mAbs to lose neutralizing activity,2 suggesting that mAb therapies have limitations against emerging SARS-CoV-2 variants. In recent years, antibody therapy strategies based on egg yolk antibodies (Immunoglobulin Y, IgY) have gained attention, where promising results have been reported in treating SARS-CoV, influenza virus, hantavirus, norovirus, and Ebola virus infections.4 Moreover, IgY antibodies have shown good thermal stability and can be stored stably in a liquid state at room temperature for 6 to 12 months. Strikingly, egg production has already been scaled up, making low-cost and large-scale IgY antibodies feasible. In the present study, we developed a broadly protective IgY antibody against SARS-CoV-2, and nasal delivery conferred significant protection against SARS-CoV-2 infection in the mice model.

A SARS-CoV-2 receptor-binding domain (RBD) trimer vaccine candidate was prepared in our previous study and showed potent protection in a nonhuman primate model.5 In this study, we used it to immunize laying hens. The immunization and sampling schedule is shown in Fig. 1a. To obtain broadly neutralizing antibodies (NAbs), the immunogens included wild type (WT) Wuhan-hu-1 strain RBD trimer (RBD-WT) and Beta VOC RBD trimer (RBD-Mu), which differ by three amino acids (K417T, E484K, and N501Y). Moreover, RBD-Mu covered all mutations in Alpha/Gamma VOCs and partial mutations in Omicron VOC. IgY antibodies were purified from eggs collected at different time points after vaccination, and the SARS-CoV-2 binding and neutralizing antibody levels were measured. RBD-specific ELISA titers gradually increased and peaked at 3880 (95% CI: 1797–8379) after the final immunization (Fig. 1b). Similar to the binding antibody, the live virus (WT) NAb geometric mean titers (GMTs) reached 110.7 (95% CI: 66.0–165.7) at 3 weeks after the second dose and increased to 1039 (609.3–1577) after the final immunization (Fig. 1c and Supplementary Fig. S1a).

To further determine the broad-spectrum neutralization potency of the developed IgY antibody, we evaluated the neutralizing activity against the SARS-CoV-2 WT strain, Beta, Delta, and Omicron VOCs using a luminescence-based lentiviral pseudovirus neutralization assay, the sera from three volunteers vaccinated with two doses of inactivated vaccines (Sinopharm) were used as the positive control. Remarkably, the IgY antibody exhibited neutralized activity of the Beta, Delta, and Omicron pseudoviruses that were comparable to that of the WT pseudovirus, with GMTs of 2041 (95% CI: 640.3–6507) for WT, 2602 (95% CI: 1178–5748) for Beta VOC, 1630 (95% CI: 577.9–4596) for Delta VOC, and 877 (95% CI: 362.2–2122) for Omicron VOC (1.2-fold increase in Beta, 1.3-fold decrease in Delta, and 2.3-fold decrease in Omicron versus WT). The GMTs of volunteers’ sera were 227 (95% CI: 96.5–531.9) for WT, 69 (95% CI: 21.3–225.3) for Beta VOC, 117 (95% CI: 35.66–386.7) for Delta VOC, and 21 (95% CI: 6.2–69.1) for Omicron VOC, with an average of 3.2-fold reduction in Beta VOC, 1.9-fold reduction in Delta VOC, and 10.8-fold reduction in Omicron VOC compared to WT (Fig. 1d and Supplementary Fig. S1b, c). These results indicate that the RBD trimer bivalent (RBD-WT and RBD-Mu) vaccine candidate can elicit broadly cross-reactive NAbs. In addition, since we only tested three sera samples as control, the results can be used to evaluate the neutralization assay in this study and are not meaningful for the cross-neutralizing activity of sera.

To evaluate the protective efficacy of the IgY antibody in vivo, ten BALB/c mice were first intranasally (IN) transduced with adenovirus expressing human angiotensin-converting enzyme 2 (hACE2) as SARS-CoV-2-sensitive animal model. Five days later, the transduced mice were randomly assigned (5:5) and IN treated with either the IgY antibody (0.1 mL) or PBS-placebo. Thirty minutes later, mice were IN challenged with 5 × 10⁵ TCID₅₀ SARS-CoV-2 hCoV-19/China/CAS-B001/2020 strain. All mice were euthanized at 3 days post-infection, viral loads in the lung and trachea were measured, and lung pathological changes were detected by H&E staining (Fig. 1e). The results showed that nasal...
delivery of IgY led to a $10^3$-fold reduction of viral RNA in the lungs, and a $10^2$-fold reduction in the trachea compared to the placebo group ($10^9$ (lung) and $10^7$ (trachea) copies/gram mean titers) (Fig. 1f, g). Notably, no live virus was detected in the lungs of the IgY treated mice, indicating effective blocking of viral propagation (Fig. 1h). In addition, the lungs of the placebo group exhibited severe pathological damage, including alveolar wall thickening, inflammatory cell infiltration, and blood cell exudation. In contrast, the pathological injuries were significantly weaker in the IgY group (Fig. 1i and Supplementary Fig. S2a, b).
Immunofluorescence results revealed a high amount of viral S protein in mice lungs of the placebo group, while only trace amounts of positive signals were detected in the IgY group (Fig. 1j). Taken together, the developed IgY antibody significantly reduced the virus loads and histopathological changes in the lungs of the mice challenged by a high load of SARS-CoV-2.

To confirm the feasibility of mass production, we produced the IgY antibody against SARS-CoV-2 with a pilot-scale production in GMP-grade manufacturing. Notably, IgY antibody could be produced at high quantity, with a final yield of 5.2 g purified antibody per liter of yolk. The purity and neutralizing activity were >98% and >2000 as detected by SDS-PAGE and the pseudovirus neutralization assay (Supplementary Fig. S3a). Additionally, the specificity of the IgY antibody was evaluated using immunofluorescence analysis. The results revealed that the IgY product could significantly recognize the S protein of live SARS-CoV-2 in Vero cells (Supplementary Fig. S3b). Thermal stability is vital for antibodies, so we tested a 3-month at 25 °C storage for the purified IgY antibody. The results revealed that the IgY product could be stably stored at 25 °C for at least 3 months, which could effectively neutralize SARS-CoV-2 WT, Beta, Delta, and Omicron VOCs. Nasal delivery of this antibody signified that passive immunoprophylaxis with antibodies via nasal spray may be an effective method for preventing post-exposure infection. In addition, the IgY antibody exhibited excellent thermal stability and high yields. Therefore, this IgY antibody promises to be supplemental pre-exposure prophylaxis to protect both individuals who have not been vaccinated and those for whom immediate immunity is required as an outbreak in a crowded area. It may also help block the route of virus transmission in pets and other animals susceptible to SARS-CoV-2.

**DATA AVAILABILITY**

The data that support the findings of this study are openly available in Science Data Bank at https://doi.org/10.11922/sciencedb.01269.

**ACKNOWLEDGEMENTS**

We thank the National Pathogen Resource Center, and the staff of BSL-3 and Xiaolian Zhang in the Institute of Microbiology, Chinese Academy of Sciences for technical support and assistance. This study was supported by National Key Technologies Research and Development Program grants 2018YFC1200500 and 2018YFC1200600 to L.Y. and 2021YFC2009053 to Y.B., Strategic Priority Research Program of Chinese Academy of Sciences XDB29010000 to W.L. and XDB29010102 to Y.B., National Natural Science Foundation of China (NSFC) (32041010), NSFC Outstanding Young Scholars (31822055), and Youth Innovation Promotion Association of CAS (2017I22) to Y.B.

**AUTHOR CONTRIBUTIONS**

L.Y. and Y.B. initiated and coordinated the project. L.Y. and Y.B. designed the experiments. W.F., S.S., N.Z., Y.Z., P.J., and J.W. conducted the experiments. L.Y. and W.F. analyzed the data. L.Y., W.F., and N.Z. wrote the manuscript. Y.B., W.L., and G.F.G. edited and discussed the manuscript.

**ADDITIONAL INFORMATION**

**Supplementary information**

The online version contains supplementary material available at https://doi.org/10.1038/s41586-021-04388-0.

**Competing interests:** The authors declare no competing interests.

**Correspondence:** Yuhai Bi (beeyh@im.ac.cn) or Limin Yang (lyyang@im.ac.cn)

**CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Infection Research and Early-Warning (CASCIRE), CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences, Beijing 100101, China; ^1^Tianjin Speerise Challenge Biotechnology Co., Ltd, Tianjin 300380, China and ^2^University of Chinese Academy of Sciences, Beijing 101409, China

These authors contributed equally: Wenhui Fan, Shanshan Sun, Ning Zhang.

Correspondence: Yuhai Bi (beeyh@im.ac.cn) or Limin Yang (lyyang@im.ac.cn)

**REFERENCES**

1. Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).
2. Liu, L. et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature (2021). https://doi.org/10.1038/s41586-021-04388-0.
3. Wu, L. et al. Broad host range of SARS-CoV-2 and the molecular basis for SARS-CoV-2 binding to cat ACE2. Cell Discov. 6, 68 (2020).
4. Zhang, Y. et al. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. PLoS Negl. Trop. Dis. 15, e0004803 (2021).
5. Yang, L. et al. A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in non-human primates. Inno- vation 2, 100140 (2021).
